# | Title | Journal | Year | Citations |
---|
1 | Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations | Cancer Research | 2008 | 574 |
2 | Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS | Annals of Oncology | 2018 | 432 |
3 | Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors | Clinical Cancer Research | 2009 | 255 |
4 | AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells | Nature Communications | 2019 | 223 |
5 | Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies | Nature Medicine | 2020 | 209 |
6 | Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort | Journal of Thoracic Oncology | 2011 | 196 |
7 | PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 | Proceedings of the National Academy of Sciences of the United States of America | 2013 | 175 |
8 | EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition | Cancer Research | 2013 | 151 |
9 | Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer | Cancer Discovery | 2016 | 132 |
10 | Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2 | Nature Communications | 2015 | 106 |
11 | Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells | Clinical Cancer Research | 2012 | 104 |
12 | Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer | Clinical Cancer Research | 2011 | 101 |
13 | Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer | Clinical Cancer Research | 2010 | 93 |
14 | A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin Antibody | Journal of Immunology | 2013 | 82 |
15 | Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer | Molecular Cancer Therapeutics | 2012 | 81 |
16 | Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status | Cancer Research | 2019 | 79 |
17 | Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2 | Oncogene | 2019 | 75 |
18 | ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Non–Small Cell Lung Cancer | Clinical Cancer Research | 2020 | 75 |
19 | Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM | Clinical Cancer Research | 2018 | 74 |
20 | Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer | Clinical Cancer Research | 2017 | 69 |
21 | Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer | Nature Communications | 2020 | 69 |
22 | Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands | Cancer Science | 2012 | 64 |
23 | KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family | Cell Cycle | 2013 | 63 |
24 | Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab | Nature Communications | 2015 | 57 |
25 | Surfactant Protein A Suppresses Lung Cancer Progression by Regulating the Polarization of Tumor-Associated Macrophages | American Journal of Pathology | 2013 | 56 |
26 | Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer | American Journal of Pathology | 2012 | 55 |
27 | Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network | American Journal of Pathology | 2011 | 54 |
28 | Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone | Cancer and Metastasis Reviews | 2007 | 47 |
29 | Adverse events of endoscopic ultrasound‐guided fine‐needle aspiration for histologic diagnosis in Japanese tertiary centers: Multicenter retrospective study | Digestive Endoscopy | 2021 | 45 |
30 | Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors | PLoS ONE | 2013 | 41 |
31 | Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs | Scientific Reports | 2015 | 40 |
32 | Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer | Journal of Thoracic Oncology | 2012 | 37 |
33 | Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients | Cancer Science | 2015 | 37 |
34 | Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations | Molecular Cancer Therapeutics | 2018 | 37 |
35 | Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis | Journal of Thoracic Oncology | 2012 | 34 |
36 | Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation | Journal of Thoracic Oncology | 2014 | 34 |
37 | mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF | PLoS ONE | 2013 | 32 |
38 | In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4‐ALK lung cancer cell line | Cancer Science | 2015 | 32 |
39 | Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance | Cancer Science | 2019 | 32 |
40 | A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer | Lung Cancer | 2021 | 32 |
41 | Genetically engineered humanized anti‐ganglioside GM2 antibody against multiple organ metastasis produced by GM2‐expressing small‐cell lung cancer cells | Cancer Science | 2011 | 31 |
42 | Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer | Cancer Science | 2020 | 31 |
43 | Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression | Oncogene | 2016 | 30 |
44 | Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer | JCO Precision Oncology | 2022 | 29 |
45 | The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor | International Journal of Cancer | 2013 | 28 |
46 | Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors | Cancer Science | 2017 | 28 |
47 | Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers | Oncogene | 2018 | 28 |
48 | Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models | Cancer Immunology, Immunotherapy | 2021 | 28 |
49 | Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer | Clinical Cancer Research | 2021 | 27 |
50 | A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma | Cancer Research | 2017 | 26 |